Guselkumab reduces disease- and mechanism-related biomarkers more than adalimumab in patients with psoriasis: a VOYAGE 1 substudy. Guselkumab reduces disease- and mechanism-related biomarkers more than adalimumab in patients with psoriasis: a VOYAGE 1 substudy

In the phase 3 VOYAGE-1 trial (ClinicalTrials.gov identifier: NCT02207231), guselkumab demonstrated superior efficacy versus placebo and the tumor necrosis factor (TNF)-α antagonist, adalimumab, in patients with moderate-to-severe plaque psoriasis (Blauvelt et al., 2017). Here, skin samples were collected from patients in VOYAGE-1 and pharmacodynamic (PD) responses to guselkumab (vs adalimumab) treatment were assessed over 48 weeks. Overall design: Psoriasis lesional skin (LS) and nonlesional skin (NL) samples were collected from 39 VOYAGE-1 trial patients who provided consent to participate in an optional skin biopsy substudy to evaluate PD effects on psoriasis transcriptomics, and were profiled using GeneChip HT HG-U133+ PM 96-Array Plate (Affymetrix, Santa Clara, CA, USA)